Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

5.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.0K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Establishing the utility of multi-platform liquid biopsy by integrating the CSF methylome and proteome in CNS tumours.

Journal of neuro-oncology·2024
Same author

Source Identification of Human Biological Materials and Its Prospect in Forensic Science.

Fa yi xue za zhi·2017
Same author

Cyclosporin A pre-incubation attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells.

Scandinavian journal of clinical and laboratory investigation·2009
Same author

Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family.

Xenobiotica; the fate of foreign compounds in biological systems·2008
Same author

Mechano-optical waveguide on-off intensity modulator.

Optics letters·2007
Same author

Regulation and immunolocalization of acyl-coenzyme A: cholesterol acyltransferase in mammalian cells as studied with specific antibodies.

The Journal of biological chemistry·1995

Related Experiment Video

Updated: Sep 1, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K

UPDATED UNDERSTANDING OF THE MOLECULAR TARGETS OF RADIOIODINE IN DIFFERENTIATED THYROID CANCER.

Y Zhang1, W Zou2, X Zhu1

  • 1Hubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.

Acta Endocrinologica (Bucharest, Romania : 2005)
|August 17, 2022
PubMed
Summary

Radioactive iodine therapy is a key treatment for thyroid cancer, but its effectiveness after reoperation for recurrent tumors is uncertain. Research explores enhancing radioiodine uptake via gene therapy for better outcomes.

Keywords:
I- uptakeRadioactive iodine (RAI)iodine transport systemthyroid cancer

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.2K

Related Experiment Videos

Last Updated: Sep 1, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.2K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Molecular Biology

Background:

  • Radioactive iodine (RAI) therapy is a standard adjuvant treatment for differentiated thyroid cancer (DTC) post-thyroidectomy.
  • RAI administration has demonstrated survival benefits in selected DTC patients.
  • The efficacy of RAI therapy following reoperation for persistent or recurrent DTC remains uncertain, potentially due to downregulated iodide transport systems.

Purpose of the Study:

  • To review the impact of RAI therapy on follicular cell-derived thyroid cancers.
  • To identify novel therapeutic targets for enhancing radioiodine uptake.
  • To improve the prognosis of thyroid cancer through optimized RAI treatment.

Main Methods:

  • Review of existing literature on radioactive iodine therapy in thyroid cancer.
  • Analysis of iodide (I-) transport pathways, including sodium iodide symporter (NIS), PENDRIN, anoctamin 1 (ANO1), and cystic fibrosis transmembrane conductance regulator (CFTR).
  • Exploration of gene therapy strategies to enhance tumor susceptibility to RAI treatment.

Main Results:

  • RAI therapy is effective as adjuvant treatment for differentiated thyroid cancer.
  • Iodide transport mechanisms are crucial for RAI uptake and efficacy.
  • Gene therapy presents a potential strategy to improve RAI targeting and effectiveness.

Conclusions:

  • Further research is needed to clarify the role of RAI therapy in recurrent DTC after reoperation.
  • Targeting iodide transport pathways offers promising avenues for enhancing RAI efficacy.
  • Optimizing radioiodine uptake through novel strategies can improve thyroid cancer prognosis.